Tridem Bioscience

Tridem Bioscience is a clinical-stage biopharmaceutical company, based in Vienna, Austria, developing a pipeline of products to address chronic diseases that can be treated with monoclonal antibodies.

Since Tridem’s foundation in 2020, we have developed a clear understanding of neoglucoconjugate vaccines for addressing different types of targets, including misfolded proteins and native self-molecules. Our knowledge and cutting-edge WISIT platform are the engines for our broad pipeline of clinical and preclinical product candidates in neurodegenerative diseases, inflammatory skin diseases and atherosclerotic cardiovascular disease (ASCVD).